FDA approves Moderna's mRNA influenza vaccine, the first of its kind
The US Food and Drug Administration has licensed mFluSIva, Moderna's messenger RNA flu shot, marking the first regulatory approval of mRNA technology for influenza.
The US Food and Drug Administration approved Moderna's influenza vaccine mFluSIva on 5 August 2026, making it the first licensed flu shot produced using messenger RNA technology — the same platform underlying the approved COVID-19 vaccines. The decision follows a Phase 3 clinical programme and comes roughly a year after federal cancellation of several mRNA vaccine development contracts.
Stat News reports that the approval was accompanied by a parallel FDA authorisation of a narcolepsy drug made by Takeda, though the influenza vaccine attracted the greater share of public commentary. An opinion piece published on the same day in Stat News, written by Jeff Coller, argues that the US remains the only major country stepping back from mRNA vaccine development at a policy level, characterising the approval as evidence that the underlying science is advancing regardless of earlier governmental decisions.
The mRNA platform encodes instructions for the immune system to recognise the influenza virus, without using live or inactivated viral material. Regulatory watchers and vaccine researchers will be interested in how annual strain-update procedures for an mRNA flu shot will be handled in practice — a process that is quicker to redesign on the mRNA platform than with egg-based or recombinant protein approaches, though real-world effectiveness data against circulating strains will emerge only after deployment.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
The US medicines regulator, the FDA, has approved a new type of flu vaccine made by the company Moderna. This vaccine uses a technology called messenger RNA — often written mRNA — which was also used in some COVID-19 vaccines. Instead of containing parts of the flu virus, the vaccine gives the body's cells instructions to recognise the virus and prepare an immune response.
This is the first time an mRNA flu vaccine has been officially approved anywhere. Researchers and public health officials are interested in the technology because it can be updated more quickly than traditional flu vaccines when the circulating strains change each year.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-08-06FDA approves Moderna's mRNA flu vaccine, the first to use the technology
-
Stat News · 2026-08-06Opinion: One year since Kennedy canceled mRNA vaccine projects, science shows how wrong he was
-
Stat News · 2026-08-06STAT+: Two FDA approvals — a new drug and a new vaccine